InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
81.97
(
-0.19%
)
Bitcoin
66,256.26
(
-0.57%
)
Post# of 2341352
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

HiddenGem69

Send PM Follow Ignore
Followers 40
Posts 1456
Boards Moderated 0
Alias Born 09/23/2013

HiddenGem69

Re: NYC Trader post# 1212837

Monday, 09/30/2013 12:41:53 PM

Monday, September 30, 2013 12:41:53 PM

Post# of 2341352
$NVLX Another apparent advantage for Nuvilex's treatment compared to the ABRAXANE-gemcitabine combination concerns the side effects (toxicities) associated with both treatments. Significant and severe drug-associated toxicities were seen with the ABRAXANE-gemcitabine combination, whereas with Nuvilex's treatment, side effects were essentially non-existent. The lack of side effects from live-cell encapsulation-ifosfamide combination is undoubtedly related to the low dose of ifosfamide used.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up